Ibrahim Aldoss

3 weeks ago | ajmc.com | Pearl Steinzor |Ibrahim Aldoss

In the PhALLCON study (NCT03589326) presented at the American Society of Clinical Oncology (ASCO) meeting, ponatinib showed higher rates of minimal residual disease (MRD) negativity compared with imatinib, which correlates with better long-term survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), explains Ibrahim Aldoss, MD, associate professor, City of Hope. This transcript was lightly edited; captions were auto-generated.

Jun 21, 2024 | onclive.com | Ibrahim Aldoss |Elias Jabbour

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic LeukemiaIbrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Jun 21, 2024 | onclive.com | Ibrahim Aldoss |Elias Jabbour

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALLIbrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Jun 21, 2024 | onclive.com | Ibrahim Aldoss |Elias Jabbour

Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALLIbrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Jun 21, 2024 | onclive.com | Ibrahim Aldoss |Elias Jabbour

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.